Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 2

2(40.0%)

N/A

2(40.0%)

Phase 1

1(20.0%)

5Total

Phase 2(2)

N/A(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT06078059Not ApplicableCompleted

Mechanisms of Treatment Effects Using Cultured, Allogeneic Mesenchymal Stromal Stem Cells (MSCs) in Knee Osteoarthritis

Role: collaborator

NCT05878977Not ApplicableRecruiting

Biomarkers in Immunotherapy of Melanoma

Role: collaborator

NCT06012604Phase 1Unknown

Treatment of Post-radiation Xerostomia With Allogeneic Mesenchymal Stromal Stem Cells

Role: collaborator

NCT00629018Phase 2Completed

Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiomyopathy

Role: collaborator

NCT01525459Unknown

Gene Expression, Immunological Status and Metabolome in Glioma Patients

Role: collaborator

NCT01436019Unknown

Study of Antibodies to Anti-TNF Agents in Juvenile Idiopathic Arthritis

Role: lead

NCT01052649Completed

Gene Expression Monitoring of Mononuclear Cells (MNC) Subpopulations and Immunological Status and Metabolome Defining of Healthy Population

Role: lead

NCT01021800Phase 2Unknown

Modulation of the Immune Response in Patients With Pancreatic Tubular Adenocarcinoma

Role: lead

NCT00947102Unknown

Influence of Gemcitabine Treatment on Immunological and Serological Profile in Patients With Pancreatic Cancer

Role: lead

All 9 trials loaded